Generic Medicine Info
May be taken with or without food.
Cardiogenic shock, 2nd and 3rd degree AV block, severe bradycardia, sick sinus syndrome, uncontrolled heart failure, severe asthma or COPD, metabolic acidosis, severe peripheral circulatory disease, untreated phaeochromocytoma.
Special Precautions
1st degree AV block. May mask symptoms of hyperthyroidism and hypoglycaemia. Patients w/ myasthenia gravis, DM. May aggravate psoriasis. Avoid abrupt withdrawal as it may precipitate thyroid storm or MI, and may exacerbate angina and ventricular arrhythmias. Patients undergoing surgery involving general anaesth. Hepatic impairment. Pregnancy and lactation. Patient Counselling May affect ability to drive or engaging in tasks that require alertness. Monitoring Parameters Monitor BP, heart rate, ECG and blood glucose.
Adverse Reactions
Fatigue, dizziness, headache, insomnia, mental depression, nightmare, anxiety, hyperesthesia or hypoesthesia. Constipation, diarrhoea, nausea, vomiting, flatulence, dyspepsia, abdominal pain, dry mouth, thirst, epigastric distress, anorexia. Dyspnoea, cough, pharyngitis, rhinitis, shortness of breath, bronchospasm, asthma. Urinary frequency, nocturia, dysuria, impotence. Rash, pruritus, sweating, reversible alopecia. Abnormal vision, sore or gritty eyes, conjunctivitis, tinnitus. Myalgia, arthralgia, lupus erythematosus-like syndrome, hypersensitivity pneumonitis, pulmonary granulomas, pleuropulmonary fibrosis, pleurisy. Reversible alterations in LFT results; dark urine, fever, malaise.
B D in 2nd & 3rd trimesters.
Drug Interactions
Additive effect w/ reserpine. Antagonises β-adrenergic stimulating effect of sympathomimetic agents. Additive negative effect on SA or AV nodal conduction w/ cardiac glycosides, nondihydropyridine Ca channel blockers. Reduced hypotensive effect w/ NSAIDs.
CIMS Class
ATC Classification
C07AB04 - acebutolol ; Belongs to the class of selective beta-blocking agents. Used in the treatment of cardiovascular diseases.
Disclaimer: This information is independently developed by CIMS based on acebutolol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in